Boston Trust Walden Corp Sells 1,373 Shares of Chemed Co. (NYSE:CHE)

Boston Trust Walden Corp decreased its holdings in Chemed Co. (NYSE:CHE) by 0.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 220,067 shares of the company’s stock after selling 1,373 shares during the period. Chemed accounts for about 0.9% of Boston Trust Walden Corp’s portfolio, making the stock its 19th biggest holding. Boston Trust Walden Corp owned approximately 1.45% of Chemed worth $132,254,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CHE. Kayne Anderson Rudnick Investment Management LLC grew its holdings in Chemed by 2.6% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 580,316 shares of the company’s stock valued at $314,868,000 after buying an additional 14,651 shares in the last quarter. William Blair Investment Management LLC grew its stake in Chemed by 2.7% during the second quarter. William Blair Investment Management LLC now owns 475,372 shares of the company’s stock valued at $257,927,000 after acquiring an additional 12,705 shares in the last quarter. Impax Asset Management Group plc increased its holdings in Chemed by 19.5% in the 2nd quarter. Impax Asset Management Group plc now owns 317,943 shares of the company’s stock valued at $172,510,000 after acquiring an additional 51,974 shares during the last quarter. TD Asset Management Inc lifted its stake in Chemed by 10.9% in the 2nd quarter. TD Asset Management Inc now owns 282,753 shares of the company’s stock worth $153,416,000 after purchasing an additional 27,800 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Chemed by 22.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 223,134 shares of the company’s stock valued at $121,068,000 after purchasing an additional 40,358 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Insider Transactions at Chemed

In related news, Director George J. Walsh III sold 400 shares of Chemed stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the completion of the transaction, the director now owns 3,046 shares in the company, valued at approximately $1,819,893.62. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director George J. Walsh III sold 400 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the completion of the sale, the director now directly owns 3,046 shares in the company, valued at $1,819,893.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the transaction, the chief executive officer now owns 105,735 shares in the company, valued at $60,229,828.05. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,144 shares of company stock worth $5,264,839 in the last three months. Insiders own 3.32% of the company’s stock.

Chemed Price Performance

Shares of CHE stock traded up $6.13 during trading hours on Friday, hitting $602.98. The stock had a trading volume of 74,047 shares, compared to its average volume of 83,469. The stock has a market capitalization of $9.13 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.44 and a beta of 0.44. Chemed Co. has a one year low of $516.03 and a one year high of $654.62. The stock’s 50-day moving average price is $586.25 and its two-hundred day moving average price is $570.14.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $5.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.59 by ($0.12). Chemed had a return on equity of 29.21% and a net margin of 12.88%. The firm had revenue of $595.88 million for the quarter, compared to analysts’ expectations of $599.20 million. During the same period last year, the company earned $4.71 earnings per share. The firm’s revenue was up 7.6% on a year-over-year basis. As a group, equities research analysts predict that Chemed Co. will post 21.77 earnings per share for the current fiscal year.

Chemed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Monday, August 12th were paid a $0.50 dividend. This is a boost from Chemed’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Monday, August 12th. Chemed’s dividend payout ratio (DPR) is presently 10.76%.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.